IP Litigators Analyze Section 112 Biopharma Post-Grant Review Patent Challenges

In The News
December 14, 2021
Capital Insights.

In the Kluwer Patent Blog, IP litigation associate Meredith Foor analyzed trends in Section 112 challenges in Post-Grant Reviews at the Patent Trial and Appeal Board, an important issue for biotechnology, pharmaceutical and chemical patent invalidity claims.